Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention

L. Pereira, Naveen; E. Farkouh, Michael; So, Derek; J. Lennon, Ryan; L. Geller, Nancy; Mathew, Verghese; R. Bell, Malcolm; Bae, Jang‐Ho; Ho Jeong, Myung; Chavez, Ivan; Gordon, Paul; Dawn Abbott, J.; Cagin, Charles; M. Baudhuin, Linnea; Fu, Yi-Ping; G. Goodman, Shaun; Hasan, Ahmed; Iturriaga, Erin; Lerman, Amir; S. Sidhu, Mandeep; Tanguay, Jean-François; Wang, Liewei; Weinshilboum, Richard; C. Welsh, Robert; Rosenberg, Yves; R. Bailey, Kent; S. Rihal, Charanjit

doi:10.1001/jama.2020.12443

Public

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention

Published in JAMA • Aug 25, 2020

Authors:

Naveen L. Pereira

Michael E. Farkouh

Derek So

Abstract

Importance: After percutaneous coronary intervention (PCI), patients with CYP2C19*2 or *3 loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic events. Whether genotype-guided selection of oral P2Y12 inhibitor therapy improves ischemic outcomes is unknown. Objectiv...

Subject

Medicine

Percutaneous coronary intervention

Clopidogrel

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!